title: Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.
abstract: The purpose of this analysis was to assess the potential of BNCT, with L-boronophenylalanine (L-BPA), as first line radiotherapy for glioblastoma multiforme (GBM). The survival of patients with newly diagnosed GBM from a phase II BNCT study was compared with those from the two arms of a phase III study with conventional radiotherapy (RT) vs. RT plus concomitant and adjuvant medication with temozolomide (TMZ). A small subgroup, for which the methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) DNA-repair gene was known, was also considered. The results indicated that the use of BNCT with BPA should be explored in a stratified randomized phase II trial in which patients with the unmethylated MGMT DNA-repair gene are offered BNCT vs. RT plus TMZ.
authors.affiliation: Green Templeton College and Particle Therapy Cancer Research Institute, University of Oxford, Oxford, UK. john.hopewell@gtc.ox.ac.uk
authors.forename: J W
authors.initials: JW
authors.lastname: Hopewell
authors.forename: T
authors.initials: T
authors.lastname: Gorlia
authors.forename: L
authors.initials: L
authors.lastname: Pellettieri
authors.forename: V
authors.initials: V
authors.lastname: Giusti
authors.forename: B
authors.initials: B
authors.lastname: H-Stenstam
authors.forename: K
authors.initials: K
authors.lastname: Sköld
mesh_terms: D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000532:radiotherapy*; D019175:DNA Methylation; D004260:DNA Repair; D005909:Glioblastoma / Q000532:radiotherapy*; D006801:Humans